Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
66
AKRO Quote, Financials, Valuation and Earnings
Last price:
$54.62
Seasonality move
:
21.2%
Day range:
$54.53 - $54.69
52-week range:
$21.34 - $58.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.70x
Volume:
2.3M
Avg. volume:
1.6M
1-year change:
76.68%
Market cap:
$4.5B
Revenue:
--
EPS (TTM):
-$3.75
Analysts' Opinion
-
Consensus RatingAkero Therapeutics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $56.00, Akero Therapeutics, Inc. has an estimated upside of 2.51% from its current price of $54.63.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $54.00 representing 100% downside risk from its current price of $54.63.
Fair Value
-
According to the consensus of 7 analysts, Akero Therapeutics, Inc. has 2.51% upside to fair value with a price target of $56.00 per share.
AKRO vs. S&P 500
-
Over the past 5 trading days, Akero Therapeutics, Inc. has overperformed the S&P 500 by 0.4% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Akero Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Akero Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Akero Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Akero Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Akero Therapeutics, Inc. reported earnings per share of -$0.99.
Enterprise value:
3.8B
EV / Invested capital:
3.92x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-227.48x
EV / Free cash flow:
-15.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$15K
Return On Assets:
-29.79%
Net Income Margin (TTM):
--
Return On Equity:
-32.14%
Return On Invested Capital:
-31.13%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$207K | -$5K | -$15K | -$1K | -- | |
| Operating Income | -$136.4M | -$269.3M | -$330M | -$81.7M | -$90.2M | |
| EBITDA | -$136.2M | -$269.3M | -$330M | -$81.7M | -$90.2M | |
| Diluted EPS | -$2.36 | -$3.75 | -$3.75 | -$1.05 | -$0.99 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $221.8M | $377.9M | $576M | $746.9M | $754.5M | |
| Total Assets | $223.5M | $379.4M | $635.3M | $817.5M | $1B | |
| Current Liabilities | $23.5M | $25.2M | $28.4M | $43.3M | $47.7M | |
| Total Liabilities | $24.9M | $35.9M | $52.2M | $79.2M | $47.9M | |
| Total Equity | $198.6M | $343.5M | $583.1M | $738.3M | $957.6M | |
| Total Debt | $1.6M | $10.6M | $25.7M | $35.7M | $289K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$122.2M | -$211.6M | -$250.2M | -$70.4M | -$67.2M | |
| Cash From Investing | -$337.9M | -$112.2M | -$330.8M | $73.1M | $56.8M | |
| Cash From Financing | $355.5M | $370.4M | $440.9M | $3.1M | -$34M | |
| Free Cash Flow | -$122.2M | -$211.6M | -$250.2M | -$70.4M | -$67.2M | |
AKRO
Sector
Market Cap
$4.5B
$28.4M
Price % of 52-Week High
93.55%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-12.39%
-1.32%
1-Year Price Total Return
76.68%
-22.19%
Beta (5-Year)
-0.399
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$54.46
200-day SMA
Buy
Level
$48.18
Bollinger Bands (100)
Buy
Level
46.48 - 54.02
Chaikin Money Flow
Buy
Level
13.6M
20-day SMA
Buy
Level
$54.32
Relative Strength Index (RSI14)
Buy
Level
70.37
ADX Line
Buy
Level
36.71
Williams %R
Sell
Level
-12.1061
50-day SMA
Buy
Level
$52.62
MACD (12, 26)
Buy
Level
0.48
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
82.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (14.4657)
Sell
CA Score
(Annual)
Level (-0.3946)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (3.7469)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, AKRO has received 1 Buy ratings 6 Hold ratings, and 0 Sell ratings. The AKRO average analyst price target in the past 3 months is $56.00.
-
Where Will Akero Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Akero Therapeutics, Inc. share price will rise to $56.00 per share over the next 12 months.
-
What Do Analysts Say About Akero Therapeutics, Inc.?
Analysts are divided on their view about Akero Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Akero Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $54.00.
-
What Is Akero Therapeutics, Inc.'s Price Target?
The price target for Akero Therapeutics, Inc. over the next 1-year time period is forecast to be $56.00 according to 7 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is AKRO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Akero Therapeutics, Inc. is a Hold. 6 of 7 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of AKRO?
You can purchase shares of Akero Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Akero Therapeutics, Inc. shares.
-
What Is The Akero Therapeutics, Inc. Share Price Today?
Akero Therapeutics, Inc. was last trading at $54.62 per share. This represents the most recent stock quote for Akero Therapeutics, Inc.. Yesterday, Akero Therapeutics, Inc. closed at $54.63 per share.
-
How To Buy Akero Therapeutics, Inc. Stock Online?
In order to purchase Akero Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get AKRO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AKRO
Sector
P/E ratio
--
23.66x
PEG ratio
-227.48x
-0.01x
P/B ratio
4.70x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
AKRO
Sector
Revenue growth
--
4.85%
Earnings growth
5.01%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.93
-$0.20
Profitability
AKRO
Sector
Profitability FY 2024
-$18K
$3.6M
Return on invested capital
-31.13%
-30.98%
Return on assets
-29.79%
-27.62%
Return on equity
-32.14%
-36.69%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Feb
27
Estimated Next Earnings Date
Feb
9
Balance Sheet
AKRO
Sector
Total cash
$737.8M
$27.2M
Short term investments
$402.8M
$25.7M
Total assets
$825.9M
$79.9M
Long term debt
$289K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
44
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
